IDT Australia Limited (ASX:IDT)

Market Cap	20.08M -28.1%
Revenue (ttm)	20.38M +3.1%
Net Income	-2.72M
EPS	-0.01
Shares Out	427.26M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,332
Open	0.0480
Previous Close	0.0470
Day's Range	0.0470 - 0.0480
52-Week Range	0.0300 - 0.0700
Beta	0.93
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 17, 2026

About IDT Australia

IDT Australia Limited engages in the research, development, manufacture, and sale of active pharmaceutical ingredients (API) and finished dose forms (FDF) products in Australia, Asia, Europe, and the United States. The company offers integrated services, including development, analytical testing, clinical packaging; and microbiological and analytical testing, clinical packaging, and pharmacy services. It also provides formulation and manufacture of speciality orals (medicinal cannabis) and advanced therapies; psychedelics and medicinal cannabis...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1975
• Employees: 100
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: IDT

Financial Performance

In fiscal year 2026, IDT Australia's revenue was 20.38 million, an increase of 3.12% compared to the previous year's 19.77 million. Losses were -2.72 million, -66.30% less than in 2025.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 11, 2026

Data Sources Report a data error